Asthma treatment and asthma prevention: A tale of 2 parallel pathways

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Three recent clinical trials used different study designs to test the hypothesis that early introduction of inhaled corticosteroids in infants and young children at high risk for the development of asthma could change the natural course of the disease. All 3 trials reached the same conclusion: treatment requirement, symptom frequency while off treatment, and lung function did not differ between children receiving active drug or placebo, with outcomes measured 2 to 4 years after randomization. These findings challenge the concept that the inflammatory processes that cause asthma symptoms and are responsive to inhaled corticosteroids are also responsible for the chronic changes in airway structure and function that are believed to predispose to the development of persistent asthma. This conclusion is supported by studies showing that bronchial hyperresponsiveness, independent of current asthma symptoms, is associated with subsequent deficits in airway function growth during childhood. Successful strategies for the prevention of asthma will require a better understanding of the genetic, environmental, and developmental factors that predispose toward inappropriate responses to airway injury. Abnormal airway remodeling and persistent dysregulation of airway tone might be the final common pathway for different disease mechanisms, and this might explain the heterogeneity of clinical phenotypic syndromes that go under the common label of "asthma.".

Original languageEnglish (US)
Pages (from-to)30-33
Number of pages4
JournalJournal of Allergy and Clinical Immunology
Volume119
Issue number1
DOIs
StatePublished - Jan 2007

Fingerprint

Asthma
Adrenal Cortex Hormones
Therapeutics
Airway Remodeling
Random Allocation
Placebos
Clinical Trials
Lung
Wounds and Injuries
Growth
Pharmaceutical Preparations

Keywords

  • Asthma
  • bronchial
  • hyperresponsiveness
  • inhaled corticosteroids
  • lung function
  • remodeling

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Asthma treatment and asthma prevention : A tale of 2 parallel pathways. / Martinez, Fernando.

In: Journal of Allergy and Clinical Immunology, Vol. 119, No. 1, 01.2007, p. 30-33.

Research output: Contribution to journalArticle

@article{7b88fcc9107645f5be09a4d37870d63e,
title = "Asthma treatment and asthma prevention: A tale of 2 parallel pathways",
abstract = "Three recent clinical trials used different study designs to test the hypothesis that early introduction of inhaled corticosteroids in infants and young children at high risk for the development of asthma could change the natural course of the disease. All 3 trials reached the same conclusion: treatment requirement, symptom frequency while off treatment, and lung function did not differ between children receiving active drug or placebo, with outcomes measured 2 to 4 years after randomization. These findings challenge the concept that the inflammatory processes that cause asthma symptoms and are responsive to inhaled corticosteroids are also responsible for the chronic changes in airway structure and function that are believed to predispose to the development of persistent asthma. This conclusion is supported by studies showing that bronchial hyperresponsiveness, independent of current asthma symptoms, is associated with subsequent deficits in airway function growth during childhood. Successful strategies for the prevention of asthma will require a better understanding of the genetic, environmental, and developmental factors that predispose toward inappropriate responses to airway injury. Abnormal airway remodeling and persistent dysregulation of airway tone might be the final common pathway for different disease mechanisms, and this might explain the heterogeneity of clinical phenotypic syndromes that go under the common label of {"}asthma.{"}.",
keywords = "Asthma, bronchial, hyperresponsiveness, inhaled corticosteroids, lung function, remodeling",
author = "Fernando Martinez",
year = "2007",
month = "1",
doi = "10.1016/j.jaci.2006.10.020",
language = "English (US)",
volume = "119",
pages = "30--33",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Asthma treatment and asthma prevention

T2 - A tale of 2 parallel pathways

AU - Martinez, Fernando

PY - 2007/1

Y1 - 2007/1

N2 - Three recent clinical trials used different study designs to test the hypothesis that early introduction of inhaled corticosteroids in infants and young children at high risk for the development of asthma could change the natural course of the disease. All 3 trials reached the same conclusion: treatment requirement, symptom frequency while off treatment, and lung function did not differ between children receiving active drug or placebo, with outcomes measured 2 to 4 years after randomization. These findings challenge the concept that the inflammatory processes that cause asthma symptoms and are responsive to inhaled corticosteroids are also responsible for the chronic changes in airway structure and function that are believed to predispose to the development of persistent asthma. This conclusion is supported by studies showing that bronchial hyperresponsiveness, independent of current asthma symptoms, is associated with subsequent deficits in airway function growth during childhood. Successful strategies for the prevention of asthma will require a better understanding of the genetic, environmental, and developmental factors that predispose toward inappropriate responses to airway injury. Abnormal airway remodeling and persistent dysregulation of airway tone might be the final common pathway for different disease mechanisms, and this might explain the heterogeneity of clinical phenotypic syndromes that go under the common label of "asthma.".

AB - Three recent clinical trials used different study designs to test the hypothesis that early introduction of inhaled corticosteroids in infants and young children at high risk for the development of asthma could change the natural course of the disease. All 3 trials reached the same conclusion: treatment requirement, symptom frequency while off treatment, and lung function did not differ between children receiving active drug or placebo, with outcomes measured 2 to 4 years after randomization. These findings challenge the concept that the inflammatory processes that cause asthma symptoms and are responsive to inhaled corticosteroids are also responsible for the chronic changes in airway structure and function that are believed to predispose to the development of persistent asthma. This conclusion is supported by studies showing that bronchial hyperresponsiveness, independent of current asthma symptoms, is associated with subsequent deficits in airway function growth during childhood. Successful strategies for the prevention of asthma will require a better understanding of the genetic, environmental, and developmental factors that predispose toward inappropriate responses to airway injury. Abnormal airway remodeling and persistent dysregulation of airway tone might be the final common pathway for different disease mechanisms, and this might explain the heterogeneity of clinical phenotypic syndromes that go under the common label of "asthma.".

KW - Asthma

KW - bronchial

KW - hyperresponsiveness

KW - inhaled corticosteroids

KW - lung function

KW - remodeling

UR - http://www.scopus.com/inward/record.url?scp=33845955753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845955753&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2006.10.020

DO - 10.1016/j.jaci.2006.10.020

M3 - Article

C2 - 17125825

AN - SCOPUS:33845955753

VL - 119

SP - 30

EP - 33

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 1

ER -